Sanofi CEO: How we’re measuring AI success

With tech powerhouses forming billion dollar alliances — from NVIDIA and OpenAI to AMD and IBM’s partnership with Anthropic — the artificial intelligence gold rush is in full swing. But one thing is clear: For business leaders, the question is no longer if they’ll use AI — it’s when and how fast.
I’ve talked to many CEOs who are not only embracing AI, but also racing to catch up. Yet many find themselves stuck either in a perpetual “pilot phase” or treating AI as another side project, rather than a core business capability. A recent MIT study revealed further insight: 95% of AI pilot projects fail — the study attributes this to investing in static tools that cannot support changing workflows. It’s hard to accelerate on AI if there are still internal debates on where to apply it, how to scale it, and how to measure it.
Advertisement
Across industries, some companies are beginning to crack the code on the ROI of AI, or ROAI. Those who recognized early on the transformative potential of AI and made bold commitments are seeing measurable results. AI is enabling them to move faster, dig deeper, and solve problems sooner. Not only is the impact felt, it’s measurable. For biopharma, ROAI isn’t a vision of the future — it’s a present reality. When applied with purpose, AI transforms how medicines are discovered, developed, and delivered, converting complexity into clarity and data into decisive action.